Vanguard Strategic Equity Investor Fund (VSEQX) seeks long-term capital growth by investing primarily in the stocks of small and midsize companies
CR Bard Inc. (BCR) has been struggling lately, but the selling pressure may be coming to an end soon.
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.64 in the third quarter of 2016, exceeding the Zacks Consensus Estimate by 9 cents and also improving 15.8% from the year-ago quarter.
CR Bard Inc. (BCR) is scheduled to report third-quarter 2016 earnings on Oct 25.
CR Bard Inc. (BCR) recently announced the receipt of an Investigational Device Exemption (IDE) approval from the U.S. FDA for its Lutonix 014 Drug Coated Balloon (DCB) to extend the primary endpoint of the product to a 6-month time frame.
CONMED Corporation (CNMD) reported second-quarter 2016 adjusted earnings of 47 cents per share, surpassing the Zacks Consensus Estimate.
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
We expect Varian Medical Systems Inc. to beat earnings when it reports third-quarter 2016 results on Jul 27.
On Jul 7, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).
CR Bard had a robust performance in international markets, extensive expenditure on product innovation and a diversified product portfolio.
Shares of CR Bard (BCR) rallied to a new 52-week high of $232.77 on Jun 29.
On Jun 20, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
On May 16, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.34 in the first quarter of 2016, exceeding the Zacks Consensus Estimate by 17 cents.
CR Bard's initiative to introduce its products in the emerging markets is delivering accretive returns, as the company continues with its sturdy performance in the international markets.
CR Bard Inc. (BCR) has been hit by a wave of product liability lawsuits over its faulty pelvic mesh products and defective vaginal-mesh implants, which could result in billions of dollars in damages.
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $ 8.34-$8.38 from the prior range of $8.25-$8.35.